Chemistry:LA-MeO

From HandWiki

LA-MeO, also known as lysergic acid ethyl-2-methoxyethylamide or as N-ethyl-N-(2-methoxyethyl)lysergamide, is a serotonin receptor modulator of the lysergamide family related to lysergic acid diethylamide (LSD).[1][2] It is the O-methyl ether derivative of the LSD metabolite lysergic acid ethyl-2-hydroxyethylamide (LEO).[1][2]

The drug shows high affinity for the serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors (Ki = 4.0 nM, 7.1 nM, and 7.8 nM, respectively).[1][2] It acts as a potent partial agonist of the serotonin 5-HT2A receptor similarly to LSD, with an EC50 of 30.3 nM and an Emax of 29.6% (relative to 8.4 nM and 22.4% in the case of LSD, respectively).[1][2]

LA-MeO was first described in the scientific literature by Jason C. Parrish of the lab of David E. Nichols at Purdue University by 2007.[1][2]

See also

  • Substituted lysergamide
  • Lysergic acid ethyl-2-hydroxyethylamide (LEO)
  • 12-Methoxy-LSD

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 "Structure–activity relationships of serotonin 5-HT 2A agonists". Wiley Interdisciplinary Reviews: Membrane Transport and Signaling 1 (5): 559–579. 2012. doi:10.1002/wmts.42. ISSN 2190-460X. https://citeseerx.ist.psu.edu/document?repid=rep1&type=pdf&doi=e28e0e22c3145af5a787c34fbedbaa8f81e1ed6b. Retrieved 22 March 2025. 
  2. ↑ 2.0 2.1 2.2 2.3 2.4 Parrish JC (30 October 2007). Toward a molecular understanding of hallucinogen action (Ph.D. thesis). Purdue University – via Purdue e-Pubs.



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:LA-MeO&oldid=4028595"